Acción A115450 HLB THERAPEUTICS CO.,LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas HLB Therapeutics Co.,Ltd.

Acciones

A115450

KR7115450009

Precio de cierre Korea S.E.
Otros sitios de cotización
 00:00:00 04/07/2024 		Varia. Cinco días. Varia. 1 de enero.
8.420 KRW -4,21 % Gráfico intradía de HLB Therapeutics Co.,Ltd. +20,46 % +92,02 %
16/05 HLB Therapeutics Co.,Ltd. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
18/03 HLB Therapeutics Co.,Ltd. informa de los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd.
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.
HLB Therapeutics Co.,Ltd. announced that it has received KRW 2.5 billion in funding
HLB Therapeutics Co.,Ltd. announced that it has received KRW 5 billion in funding
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors
Oblato, Inc. announced that it has received KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd.
HLB Therapeutics to Raise 13 Billion Won via Stock Sale
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 13.0088 billion in funding from HLB Co., Ltd.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción A115450
  4. Noticias HLB Therapeutics Co.,Ltd.
  5. Otros idiomas